YNL108C Antibody

What is YNL108C and why is it significant for research?

YNL108C (also known as HUF) is an uncharacterized protein found in Saccharomyces cerevisiae strain 204508/S288c (Baker's yeast). The protein is significant for research in yeast genetics and cellular functions. The antibody against YNL108C serves as an important tool for detecting and studying this protein in various experimental contexts. While the exact function of YNL108C remains under investigation, antibodies targeting this protein enable researchers to explore its expression patterns, localization, and potential interactions with other cellular components .

What specific applications is the YNL108C antibody validated for?

The YNL108C polyclonal antibody has been specifically validated for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot applications. These techniques allow researchers to detect and quantify the presence of YNL108C protein in yeast samples. When conducting these assays, it's essential to ensure proper identification of the antigen. The antibody has not been specifically validated for immunohistochemistry, immunofluorescence, or immunoprecipitation, though researchers may test its efficacy in these applications with appropriate controls .

What are the optimal storage conditions for maintaining YNL108C antibody activity?

For optimal preservation of antibody activity, the YNL108C antibody should be stored at either -20°C or -80°C immediately upon receipt. Repeated freeze-thaw cycles should be avoided as they can compromise antibody functionality. The antibody is supplied in a liquid formulation containing 0.03% Proclin 300 as a preservative, along with 50% glycerol and 0.01M PBS at pH 7.4, which helps maintain stability during storage. If small volumes become entrapped in the seal of the product vial during shipment or storage, a brief centrifugation on a tabletop centrifuge is recommended to dislodge any liquid in the container's cap .

What controls should be included when using YNL108C antibody in experiments?

These controls are essential for validating experimental results and distinguishing specific signals from background noise. Careful interpretation of controls helps ensure reproducibility and reliability of findings when using YNL108C antibody in research applications.

How can epitope mapping be performed to characterize the binding sites of YNL108C antibody?

Epitope mapping for YNL108C antibody involves several methodological approaches. Begin with peptide array analysis using overlapping synthetic peptides spanning the entire YNL108C protein sequence. Each peptide (typically 15-20 amino acids long with 5-10 amino acid overlaps) is immobilized on a membrane or microarray and probed with the antibody. Strong signals indicate potential epitope regions. This can be followed by alanine scanning mutagenesis where individual amino acids in the identified regions are systematically replaced with alanine to determine critical binding residues. For higher resolution, X-ray crystallography or cryo-electron microscopy of antibody-antigen complexes can provide atomic-level detail of binding interfaces. Using computational approaches like molecular docking can supplement experimental data. Compare your epitope mapping results with known protein domains to infer potential functional significance of the antibody binding .

What strategies can be employed to improve specificity when using YNL108C antibody in complex yeast lysates?

Improving specificity when working with YNL108C antibody in complex yeast lysates requires a multi-faceted approach. First, optimize antibody concentrations through titration experiments (typically testing 1:500 to 1:5000 dilutions) to determine the minimum concentration yielding specific signal. Pre-absorb the antibody with non-specific proteins by incubating with yeast lysates lacking YNL108C protein before use. Implement stringent washing protocols in immunoassays, using detergents like 0.1% Tween-20 in TBS to reduce non-specific binding. Adjust blocking solutions (consider 5% BSA instead of milk for phosphorylated targets) and blocking times (2-4 hours at room temperature or overnight at 4°C). For Western blots, use gradient gels (4-12%) to improve separation and PVDF membranes instead of nitrocellulose for better protein retention. Consider two-dimensional electrophoresis to separate proteins by both isoelectric point and molecular weight before immunodetection. Finally, validate findings by orthogonal approaches such as mass spectrometry identification of immunoprecipitated proteins .

How does using the YNL108C polyclonal antibody compare to monoclonal antibodies in research applications?

The YNL108C polyclonal antibody differs fundamentally from monoclonal antibodies in several research-relevant aspects:

This comparison demonstrates why polyclonal antibodies like the YNL108C antibody are often preferred for initial protein characterization and detection, while monoclonal antibodies offer advantages for highly specific applications. Recent advances in antibody engineering, as demonstrated in MAGE (Monoclonal Antibody GEnerator) technology, are beginning to address limitations in traditional antibody discovery approaches .

What is the optimal protocol for using YNL108C antibody in Western blot applications?

The optimal protocol for Western blot using YNL108C antibody involves several critical steps. Begin with proper sample preparation by lysing yeast cells in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8.0) containing protease inhibitors. Sonicate briefly and centrifuge at 14,000×g for 10 minutes at 4°C to remove cell debris. Determine protein concentration using Bradford or BCA assay. Separate 20-50μg of protein per lane on a 10-12% SDS-PAGE gel at 100V until the dye front reaches the bottom. Transfer proteins to PVDF membrane (0.45μm) at 100V for 1 hour in cold transfer buffer containing 20% methanol. Block the membrane with 5% BSA in TBST (TBS + 0.1% Tween-20) for 1 hour at room temperature. Incubate with YNL108C primary antibody at 1:1000 dilution in blocking buffer overnight at 4°C. Wash 3 times for 5 minutes each with TBST. Incubate with HRP-conjugated anti-rabbit secondary antibody at 1:5000 dilution for 1 hour at room temperature. Wash 3 times for 10 minutes each with TBST. Develop using enhanced chemiluminescence substrate and image the membrane. The YNL108C protein should be detected at the expected molecular weight, though post-translational modifications may affect migration patterns .

How can YNL108C antibody be utilized effectively in ELISA experiments?

For effective ELISA using YNL108C antibody, follow this methodological approach: Coat high-binding 96-well plates with 100μl/well of purified YNL108C protein (for direct ELISA) or capture antibody (for sandwich ELISA) at 1-10μg/ml in carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C. Wash three times with PBST (PBS + 0.05% Tween-20). Block with 300μl/well of 3% BSA in PBST for 2 hours at room temperature. For direct ELISA, add YNL108C antibody at optimized dilutions (starting with 1:1000 in blocking buffer) and incubate for 2 hours at room temperature. For sandwich ELISA, add samples containing YNL108C protein, incubate for 2 hours, wash, then add YNL108C antibody. After incubation with primary antibody, wash 5 times with PBST. Add 100μl/well HRP-conjugated anti-rabbit secondary antibody (1:5000 in blocking buffer) and incubate for 1 hour at room temperature. Wash 5 times with PBST. Add 100μl/well TMB substrate and incubate in darkness for 15-30 minutes. Stop the reaction with 50μl/well 2N H₂SO₄. Read absorbance at 450nm with reference at 630nm. Create a standard curve using known concentrations of YNL108C protein for quantification. Each plate should include negative controls and serially diluted positive controls to ensure assay validity .

What considerations are important when using YNL108C antibody in multiplexed immunoassays?

When incorporating YNL108C antibody into multiplexed immunoassays, several critical factors must be considered. First, validate antibody specificity independently before multiplexing to confirm there is no cross-reactivity with other targets in your panel. Optimize antibody concentrations separately for each detection system, as optimal concentrations may differ from single-target assays. Carefully select compatible fluorophores or reporter systems with minimal spectral overlap to avoid signal bleed. If using differently labeled secondary antibodies, ensure they recognize different primary antibody isotypes or species to prevent cross-recognition. Establish appropriate blocking protocols using a mixture of proteins (e.g., 2% BSA, 2% normal serum, 0.1% casein) to minimize non-specific binding across all antibodies in the panel. Implement stringent washing steps between antibody applications to reduce background. Include single-stain controls for each antibody to set proper compensation when using flow cytometry or multispectral imaging. For bead-based multiplexed assays, optimize coupling efficiency of YNL108C antibody to beads and test for cross-reactivity between capture and detection antibodies. Validate the entire multiplex assay against single-plex measurements to ensure comparable sensitivity and specificity when antibodies are used in combination .

What are common causes of false positives when using YNL108C antibody, and how can they be mitigated?

False positives when using YNL108C antibody can arise from multiple sources that must be systematically addressed. Cross-reactivity with similar epitopes in non-target proteins is a primary concern, especially given that YNL108C is an uncharacterized protein. Mitigate this by performing comprehensive specificity testing using knockout controls and pre-absorption with related proteins. Non-specific binding to Fc receptors in yeast samples can be reduced by including proper blocking agents (1-2% BSA or commercial blocking buffers) in your protocol. Insufficient washing frequently causes high background; implement more stringent washing steps (4-5 washes of 5-10 minutes each) with PBST or TBST containing 0.1-0.3% Tween-20. Over-development in Western blots leads to artifactual bands; optimize exposure times and use a range of antibody dilutions (1:500 to 1:5000) to determine optimal signal-to-noise ratio. Sample overloading can create non-specific interactions; standardize protein loading (20-50μg for Western blots) and validate with loading controls. Secondary antibody cross-reactivity is eliminated by running secondary-only controls. Finally, endogenous peroxidase or phosphatase activity in yeast samples can be quenched using 0.3% H₂O₂ for 15-30 minutes before antibody application in immunohistochemical applications .

How should researchers approach epitope masking and retrieval when the YNL108C antibody yields inconsistent results?

When facing inconsistent results with YNL108C antibody due to potential epitope masking, implement a systematic epitope retrieval strategy. For fixed samples, test multiple fixation methods (4% paraformaldehyde, 70% ethanol, methanol-acetone) as chemical fixatives can differentially affect epitope accessibility. If using formaldehyde-fixed samples, perform heat-induced epitope retrieval by heating samples to 95-100°C for 10-20 minutes in citrate buffer (pH 6.0) or EDTA buffer (pH 8.0), followed by cooling to room temperature. Alternatively, try enzymatic retrieval using proteinase K (10-20μg/ml for 10-20 minutes at 37°C), which can unmask epitopes by partially digesting proteins cross-linked during fixation. For native protein analysis, test different detergents (0.1-0.5% Triton X-100, NP-40, or CHAPS) to improve membrane permeabilization without disrupting epitope structure. Consider protein denaturation effects by comparing reducing versus non-reducing conditions, as disulfide bonds may affect epitope presentation. If the YNL108C antibody was raised against a recombinant protein, conformational differences between the immunogen and native protein may exist; try denaturing conditions for linear epitope detection. For complex samples, pre-clear with Protein A/G before immunoprecipitation to remove proteins that bind non-specifically. Document all optimization steps methodically, comparing signal intensity, background, and reproducibility to establish the most reliable protocol for your specific experimental system .

What strategies can address potential cross-reactivity issues with YNL108C antibody in different yeast strains?

Addressing cross-reactivity of YNL108C antibody across different yeast strains requires a comprehensive validation strategy. First, perform sequence alignment analysis of YNL108C protein across target strains to identify regions of variability that might affect antibody recognition. For experimental validation, prepare Western blots with protein lysates from multiple yeast strains in parallel, including a YNL108C knockout as negative control. Analyze band patterns carefully—multiple bands or bands at unexpected molecular weights may indicate cross-reactivity. Implement peptide competition assays by pre-incubating the antibody with excess purified YNL108C peptide (10-100x molar excess) before application; specific signals should be significantly reduced while cross-reactive signals may persist. Consider epitope-specific validation using synthetic peptides representing different regions of YNL108C to identify which regions are recognized across strains. For critical applications, perform immunoprecipitation followed by mass spectrometry to definitively identify all proteins being recognized by the antibody in each strain. Titrate antibody concentrations systematically (testing 1:500 to 1:10,000 dilutions) to find optimal signal-to-noise ratio for each strain. Use more stringent washing conditions (0.2-0.3% Tween-20 in TBS or PBS) when working with strains showing potential cross-reactivity. Finally, consider raising strain-specific antibodies if cross-reactivity cannot be eliminated through optimization .

How can YNL108C antibody be utilized in protein-protein interaction studies?

Utilizing YNL108C antibody for protein-protein interaction studies requires multiple complementary approaches. For co-immunoprecipitation (Co-IP), lyse yeast cells in mild detergent buffer (1% NP-40, 150mM NaCl, 50mM Tris-HCl pH 7.5) with protease inhibitors. Pre-clear lysate with Protein A/G beads for 1 hour at 4°C. Incubate 1-5μg of YNL108C antibody with 500-1000μg of pre-cleared lysate overnight at 4°C with gentle rotation. Add 30-50μl Protein A/G beads and incubate for 2-4 hours. Wash extensively (4-5 times) with lysis buffer. Elute bound proteins with SDS sample buffer and analyze by Western blot using antibodies against suspected interaction partners. For proximity ligation assay (PLA), fix yeast cells with 4% paraformaldehyde for 15 minutes, permeabilize with 0.1% Triton X-100, and block with 3% BSA. Incubate with YNL108C antibody and antibody against potential interaction partner overnight at 4°C. Follow with species-specific PLA probes and perform ligation and amplification according to manufacturer's protocol. For bimolecular fluorescence complementation (BiFC), fuse the N-terminal fragment of a fluorescent protein to YNL108C and C-terminal fragment to potential partners, then visualize interactions through fluorescence microscopy. Validate all interactions with reciprocal experiments and controls including IgG control antibodies and lysates from YNL108C-deficient strains .

What considerations are important when using YNL108C antibody for chromatin immunoprecipitation (ChIP) experiments?

When adapting YNL108C antibody for chromatin immunoprecipitation (ChIP) experiments, several critical methodological considerations must be addressed. First, optimize crosslinking conditions—typically 1% formaldehyde for 10-15 minutes at room temperature—as inadequate or excessive crosslinking can significantly impact results. For yeast cells, enzymatic digestion of cell walls using zymolyase (10-30 units/ml for 30 minutes at 30°C) prior to lysis may be necessary for efficient extraction. Sonication parameters must be carefully calibrated to generate DNA fragments of appropriate size (200-500bp); typically 10-15 cycles of 30 seconds on/30 seconds off at medium power works well for yeast chromatin. Pre-clear chromatin with Protein A/G beads coupled with non-immune IgG to reduce non-specific binding. Determine optimal antibody concentration empirically, typically starting with 2-5μg per ChIP reaction and adjust based on enrichment results. Include appropriate controls: input chromatin (pre-immunoprecipitation sample), non-immune IgG (negative control), and antibody against a known DNA-binding protein (positive control). Perform stringent washing steps with increasing salt concentrations (150-500mM NaCl) to reduce background. For elution and reversal of crosslinks, incubate samples at 65°C for 4-6 hours in elution buffer. Purify DNA using phenol-chloroform extraction or commercial kits optimized for ChIP. Validate enrichment using quantitative PCR before proceeding to sequencing. If YNL108C is not known to directly bind DNA, consider ChIP-reChIP approaches to investigate protein complexes or use a tagged version of YNL108C if antibody efficiency is suboptimal .

How does the combination approach used in antibody therapeutics like REGEN-COV inform research strategies with YNL108C antibody?

The combinatorial antibody approach exemplified by REGEN-COV offers valuable strategic insights for YNL108C antibody research. REGEN-COV's success demonstrates that using non-competing antibodies targeting distinct epitopes simultaneously provides superior binding specificity and resistance to target mutations. For YNL108C research, this suggests developing complementary antibodies recognizing different epitopes of the protein for more robust detection. Similarly to how REGEN-COV's combination prevents viral escape through multiple binding sites, using antibody cocktails against YNL108C could mitigate issues with epitope masking or post-translational modifications that might obscure single epitopes. The REGEN-COV development process incorporated structural biology approaches (cryo-EM) to confirm non-overlapping binding, suggesting that researchers should characterize epitope binding of different YNL108C antibodies to develop optimal combinations. Additionally, REGEN-COV's design process, which selected antibodies based on both individual potency and complementary properties, indicates that YNL108C antibody panels should be evaluated not just individually but also in combinations for potential synergistic effects in detection sensitivity. The resistance to escape variants seen with antibody combinations in REGEN-COV suggests that combining multiple YNL108C antibodies could improve reliable detection across yeast strain variations or mutant forms of the protein .

How might emerging AI-based antibody generation technologies like MAGE impact future research with YNL108C antibody?

Emerging AI-based antibody generation technologies like MAGE (Monoclonal Antibody GEnerator) could revolutionize YNL108C antibody research through several transformative mechanisms. MAGE employs protein Large Language Models (LLMs) to generate novel paired antibody sequences against specified antigens, potentially allowing for the rapid design of customized antibodies targeting specific epitopes of YNL108C without traditional immunization processes. This approach could overcome current limitations where commercially available YNL108C antibodies may target suboptimal epitopes or have limited specificity across yeast strains. MAGE's capability to design antibodies requiring only the antigen sequence as input would enable researchers to generate specialized YNL108C antibodies optimized for particular applications (e.g., conformational epitopes for native protein detection versus linear epitopes for denatured applications). The technology's demonstrated ability to generate diverse antibody sequences with experimentally validated binding specificity suggests it could produce YNL108C antibodies with superior characteristics compared to current polyclonal preparations, including better specificity, reduced batch-to-batch variability, and optimized binding kinetics. Furthermore, MAGE-designed antibodies could be rationally engineered to function in specific experimental conditions (pH, temperature, detergent compatibility) that challenge conventional antibodies. Eventually, researchers might utilize such platforms to develop application-specific YNL108C antibody panels, each member optimized for a distinct research methodology such as Western blotting, immunofluorescence, or ChIP-seq, eliminating the current need to empirically test antibodies across applications .

What research protocols could be developed to study post-translational modifications of YNL108C using specific antibodies?

Studying post-translational modifications (PTMs) of YNL108C requires sophisticated research protocols utilizing modification-specific antibodies. Begin by performing bioinformatic analysis to predict potential PTM sites using tools like NetPhos, UbPred, and SUMOsp. Generate or acquire antibodies specifically targeting predicted modifications (phospho-, ubiquitin-, SUMO-, acetyl-, or glycosyl-specific). For phosphorylation studies, treat yeast cultures with phosphatase inhibitors (50mM NaF, 10mM Na₃VO₄) during lysis to preserve phosphorylation states. Perform initial screening via Western blot comparing untreated samples with those treated with lambda phosphatase (400 units/100μg protein, 30°C for 30 minutes) to confirm specificity for phosphorylated forms. For enrichment of modified proteins, implement immunoprecipitation with PTM-specific antibodies followed by detection with YNL108C antibody, or vice versa. To identify specific modification sites, combine immunoprecipitation with mass spectrometry analysis; digest immunoprecipitated YNL108C with trypsin and analyze peptides by LC-MS/MS, looking for mass shifts characteristic of specific modifications. For temporal dynamics of modifications, synchronize yeast cultures and collect time-course samples following environmental stimuli or cell cycle progression. Utilize proximity ligation assay (PLA) combining YNL108C antibody with modification-specific antibodies to visualize modified YNL108C in situ. For functional studies, correlate modification states with YNL108C localization or interaction partners through cellular fractionation or co-immunoprecipitation experiments. Create a comprehensive PTM map of YNL108C by integrating data from multiple approaches, potentially revealing regulatory mechanisms controlling this uncharacterized protein's function .

How can researchers evaluate and improve the reproducibility of experiments using YNL108C antibody across different laboratories?

Improving cross-laboratory reproducibility with YNL108C antibody requires implementation of standardized practices and rigorous validation protocols. Establish a detailed antibody validation profile including Western blot images, immunoprecipitation results, and specificity tests against YNL108C knockout samples. Document this profile using structured reporting formats like the Antibody Validation Reporting Template. Create standardized operating procedures (SOPs) specifying exact buffer compositions, incubation times, temperatures, and washing protocols for each application. Implement digital laboratory notebooks for comprehensive documentation of all experimental parameters, including lot numbers of antibodies and reagents, equipment settings, and environmental conditions. Establish a centralized biorepository of reference samples (purified YNL108C protein, wild-type and knockout yeast lysates) that can be distributed to different laboratories for calibration purposes. Develop quantitative quality control metrics such as signal-to-noise ratios and coefficient of variation thresholds that experiments must meet to be considered valid. Conduct multi-laboratory ring trials where identical samples are processed using the same protocol across different facilities to identify sources of variability. Implement automated image analysis workflows to reduce subjective interpretation of results. Consider replacing traditional Western blot with more quantitative techniques like automated capillary Western systems that provide better reproducibility. Use recombinant antibody technology where possible to eliminate polyclonal batch-to-batch variation. Share all raw data along with processed results when publishing, enabling independent verification. Finally, establish a community database of YNL108C antibody experimental results where researchers can compare their findings with historical data and identify potential sources of variability .